The estimated Net Worth of Capital Management Ii, Llc ... is at least $35.8 Milión dollars as of 4 September 2019. Capital Llc owns over 115,900 units of Aerie Pharmaceuticals Inc stock worth over $35,844,774 and over the last 5 years Capital sold AERI stock worth over $0.
Capital has made over 5 trades of the Aerie Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 115,900 units of AERI stock worth $2,140,673 on 4 September 2019.
The largest trade Capital's ever made was buying 539,555 units of Aerie Pharmaceuticals Inc stock on 12 August 2019 worth over $13,343,195. On average, Capital trades about 186,091 units every 5 days since 2019. As of 4 September 2019 Capital still owns at least 2,350,477 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Capital Llc stock trades at the bottom of the page.
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra a Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: